ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Takeda is shuttering its San Francisco R&D site and shifting some biologics research to its San Diego facility. The move comes several months after the Japanese firm said it will cut 9% of its workforce, or 2,800 employees, and consolidate R&D around the world. Takeda says the plan to merge California activities will “enhance communication and collaboration.” The San Diego site will focus on using structure-based drug discovery and antibody technology to develop drugs for metabolic diseases, cancer, and immunology.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter